Literature DB >> 23719040

Mortality and reintervention following elective abdominal aortic aneurysm repair.

Mohammad Qadura1, Farhan Pervaiz, John A Harlock, Ashraf Al-Azzoni, Forough Farrokhyar, Kamyar Kahnamoui, David A Szalay, Theodore Rapanos.   

Abstract

BACKGROUND: The objective of this study is to provide an up-to-date meta-analysis on the short- and long-term mortality rates of elective repair of abdominal aortic aneurysms (AAAs) via the open and endovascular approaches.
METHODS: MEDLINE, EMBASE, and Cochrane Central Register of Controlled trials, conference proceeding from major vascular meetings were searched for randomized trials comparing open vs elective endovascular aneurysm repair (EVAR) of AAAs. A random-effects model was used for analysis. Risk ratio (RR) and 95% confidence intervals (CIs) of open vs EVAR were calculated for short- and long-term mortality and reintervention rates.
RESULTS: The analysis encompassed four randomized controlled trials with a total of 2783 patients. The open repair group resulted in significantly increased 30-day postoperative all-cause mortality compared with EVAR repair group (3.2% vs 1.2%; RR, 2.81; 95% CI, 1.60-4.94); however, there is no statistical difference in the long-term all-cause mortality between both groups (RR, 0.97; 95% CI, 0.86-1.10). Interestingly, fewer patients underwent reintervention procedures in the open repair group compared with those who had EVAR repair (9.3% vs 18.9%; RR, 0.49; 95% CI, 0.40-0.60), but this finding is doubtful due to the large heterogeneity. Lastly, no statistical difference in long-term mortality rates attributable to cardiovascular disease (CVD), aneurysm related, or stroke were found between the two types of repair.
CONCLUSIONS: Results of this meta-analysis demonstrate that the 30-day all-cause mortality rate is higher with open than with EVAR repair; however, there is no statistical difference in the long-term all-cause and cause-specific mortality between both groups. The reintervention rate attributable to procedural complication was higher in the EVAR group. Because of the equivalency of long-term outcomes and the short-term benefits of EVAR, an endovascular-first approach to AAAs can be supported by the meta-analysis.
Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23719040     DOI: 10.1016/j.jvs.2013.02.013

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

1.  Cauda equina syndrome: an uncommon symptom of aortic diseases.

Authors:  Fuliang He; Tong Xing; Fang Yu; Hongchuan Li; Xiutong Fang; Hongxing Song
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 2.  The Abdominal Aortic Aneurysm and Intraluminal Thrombus: Current Concepts of Development and Treatment.

Authors:  Aleksandra Piechota-Polanczyk; Alicja Jozkowicz; Witold Nowak; Wolf Eilenberg; Christoph Neumayer; Tadeusz Malinski; Ihor Huk; Christine Brostjan
Journal:  Front Cardiovasc Med       Date:  2015-05-26

3.  Suitability of the Aortic Neck Anatomy for Endovascular Aneurysm Repair in Korean Patients with Abdominal Aortic Aneurysm.

Authors:  Deokbi Hwang; Jihye Kim; Hyung-Kee Kim; Seung Huh
Journal:  Vasc Specialist Int       Date:  2020-06-30

4.  Clinical evaluation of endovascular repair of abdominal aortic aneurysm based on long-term experiences.

Authors:  Piotr Kulig; Krzysztof Lewandowski; Bogusław Rudel; Maciej Chwała; Marek Piwowarczyk; Wojciech Mrowiecki
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2020-03-27       Impact factor: 1.195

5.  Screening for Abdominal Aortic Aneurysms and Risk Factors in 65-Year-Old Men in Oslo, Norway.

Authors:  Toril Rabben; Saira Mauland Mansoor; Dag Bay; Jon Otto Sundhagen; Cecilia Guevara; Jorgen Joakim Jorgensen
Journal:  Vasc Health Risk Manag       Date:  2021-09-10

6.  Recoupling of eNOS with folic acid prevents abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E null mice.

Authors:  Kin Lung Siu; Xiao Niu Miao; Hua Cai
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.